Results 131 to 140 of about 431,919 (294)

The effect of diagnosis-related group policy on treatment cost and treatment efficiency of inpatients with coronary heart disease in Xinjiang: an interrupted time series analysis. [PDF]

J Glob Health
Wang N, Yi H, Yang J, Aierken A, Wushouer H, Han S, Yao W.   +6 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Comparative analysis of bowel preparation quality for colonoscopy: a survey of outpatients and inpatients. [PDF]

BMC Gastroenterol
Jiang L, Wu M, Dong C, Lei Y, Li J, Chen T, Zhao P, Deng Q, Rong J, Chen Z, Sun X.   +10 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Disparities in Distress Symptoms Among Cancer Inpatients, Outpatients and Relatives Through Introducing and Evaluating Digital Distress Screening. [PDF]

Psychooncology
Dornbrach T, Volz M, Seufferlein T, Kestler H, Hönig K.   +4 more
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Study on the mortality risk and predictive model for COVID-19 inpatients with pneumonia manifestations. [PDF]

PeerJ
Li Z, Liang J, Lu K, Tang S, Huang J, Zhang J, Zou J, Huang D, Xie C, Zeng L, Wang Z, Deng Y, Lu J.   +12 more
europepmc   +1 more source

The prevalence of medication-related adverse events in inpatients—a systematic review and meta-analysis

European Journal of Clinical Pharmacology, 2017
O. Laatikainen, O. Laatikainen, J. Miettunen, J. Miettunen, S. Sneck, H. Lehtiniemi, H. Lehtiniemi, O. Tenhunen, M. Turpeinen, M. Turpeinen   +9 more
semanticscholar   +1 more source

Inpatient Insights [PDF]

Pharmacy Today, 2021
openaire   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source